Grove Bank & Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Grove Bank & Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39K	Sell	100 -400	-80%	-$13.3K	﹤0.01%	766
2026 Q1	$15.1K	Sell	500 -500	-50%	-$16.1K	﹤0.01%	574
2025 Q4	$31.2K	Buy	1,000 +750	+300%	+$18.5K	﹤0.01%	485
2025 Q3	$5.05K	Buy	+250	New	+$4.39K	﹤0.01%	704
2017 Q3	–	Sell	-1,540	Closed	-$51K	–	655
2017 Q2	$51K	Buy	1,540 +1,090	+242%	+$33.7K	0.03%	252
2017 Q1	$14K	Buy	450 +288	+178%	+$9.83K	0.01%	322
2016 Q4	$6K	Hold	162	–	–	﹤0.01%	443
2016 Q3	$7K	Hold	162	–	–	0.01%	226
2016 Q2	$8K	Hold	162	–	–	0.01%	216
2016 Q1	$9K	Hold	162	–	–	0.01%	228
2015 Q4	$11K	Buy	+162	New	+$10K	0.01%	268

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Grove Bank & Trust's TEVA Position: Q2 2026 in Review

Grove Bank & Trust reduced its Teva Pharmaceuticals (TEVA) stake by 80% in Q2 2026, selling an estimated $13.3K and leaving 100 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Grove Bank & Trust first reported a position in TEVA in Q4 2015 and has held it in 11 quarters since. The position peaked at $51K in Q2 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Grove Bank & Trust held 100 shares of Teva Pharmaceuticals worth $3.39K as of Q2 2026.
Grove Bank & Trust sold 400 Teva Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
Teva Pharmaceuticals made up ﹤0.01% of Grove Bank & Trust's portfolio in Q2 2026, its #766 holding.
Grove Bank & Trust first reported a position in Teva Pharmaceuticals in Q4 2015 and has held it in 11 quarters since.
Grove Bank & Trust's Teva Pharmaceuticals position peaked at $51K in Q2 2017.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.